Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection

dc.contributor.authorEngle, Sarah M.
dc.contributor.authorChang, Ching-Yun
dc.contributor.authorUlrich, Benjamin J.
dc.contributor.authorSatterwhite, Allyson
dc.contributor.authorHayes, Tristan
dc.contributor.authorRobling, Kim
dc.contributor.authorSissons, Sean E.
dc.contributor.authorSchmitz, Jochen
dc.contributor.authorTepper, Robert S.
dc.contributor.authorKaplan, Mark H.
dc.contributor.authorSims, Jonathan T.
dc.contributor.departmentMicrobiology and Immunology, School of Medicineen_US
dc.date.accessioned2023-06-15T11:43:33Z
dc.date.available2023-06-15T11:43:33Z
dc.date.issued2021
dc.description.abstractThe pathogenesis of atopic dermatitis (AD) results from complex interactions between environmental factors, barrier defects, and immune dysregulation resulting in systemic inflammation. Therefore, we sought to characterize circulating inflammatory profiles in pediatric AD patients and identify potential signaling nodes which drive disease heterogeneity and progression. We analyzed a sample set of 87 infants that were at high risk for atopic disease based on atopic dermatitis diagnoses. Clinical parameters, serum, and peripheral blood mononuclear cells (PBMCs) were collected upon entry, and at one and four years later. Within patient serum, 126 unique analytes were measured using a combination of multiplex platforms and ultrasensitive immunoassays. We assessed the correlation of inflammatory analytes with AD severity (SCORAD). Key biomarkers, such as IL-13 (rmcorr=0.47) and TARC/CCL17 (rmcorr=0.37), among other inflammatory signals, significantly correlated with SCORAD across all timepoints in the study. Flow cytometry and pathway analysis of these analytes implies that CD4 T cell involvement in type 2 immune responses were enhanced at the earliest time point (year 1) relative to the end of study collection (year 5). Importantly, forward selection modeling identified 18 analytes in infant serum at study entry which could be used to predict change in SCORAD four years later. We have identified a pediatric AD biomarker signature linked to disease severity which will have predictive value in determining AD persistence in youth and provide utility in defining core systemic inflammatory signals linked to pathogenesis of atopic disease.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationEngle SM, Chang CY, Ulrich BJ, et al. Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection [published online ahead of print, 2021 Nov 30]. Clin Exp Immunol. 2021;207(3):253-262. doi:10.1093/cei/uxab009en_US
dc.identifier.urihttps://hdl.handle.net/1805/33770
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.isversionof10.1093/cei/uxab009en_US
dc.relation.journalClinical & Experimental Immunologyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePMCen_US
dc.subjectAtopic dermatitisen_US
dc.subjectPediatricen_US
dc.subjectSignaling nodesen_US
dc.subjectInflammatory analytesen_US
dc.subjectBiomarkersen_US
dc.titlePredictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collectionen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
uxab009.pdf
Size:
2.16 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: